New Actions on Actionable Mutations in Lung Cancers

Xiuning Le¹, Yasir Y Elamin¹, Jianjun Zhang^{1

2}

Affiliations

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Editorial

Xiuning Le et al. Cancers (Basel). 2023.

. 2023 May 26;15(11):2917.

doi: 10.3390/cancers15112917.

Xiuning Le¹, Yasir Y Elamin¹, Jianjun Zhang^{1

2}

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Abstract

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect patients' response to treatments [...].

The authors declare no conflict of interest.

1. Carr T.H., McEwen R., Dougherty B., Johnson J.H., Dry J.R., Lai Z., Ghazoui Z., Laing N.M., Hodgson D.R., Cruzalegui F., et al. Defining actionable mutations for oncology therapeutic development. Nat. Rev. Cancer. 2016;16:319–329. doi: 10.1038/nrc.2016.35. - DOI - PubMed
1. White M.N., Piotrowska Z., Stirling K., Liu S.V., Banwait M.K., Cunanan K., Sequist L.V., Wakelee H.A., Hausrath D., Neal J.W. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clin. Lung Cancer. 2021;22:201–209. doi: 10.1016/j.cllc.2021.01.010. - DOI - PMC - PubMed
1. Elamin Y.Y., Gomez D.R., Antonoff M.B., Robichaux J.P., Tran H., Shorter M.K., Bohac J.M., Negrao M.V., Le X., Rinsurogkawong W., et al. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC) Clin. Lung Cancer. 2019;20:43–47. doi: 10.1016/j.cllc.2018.09.015. - DOI - PubMed
1. Wu T.C., Lin C.C. Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors. J. Thorac. Oncol. 2022;17:1063–1066. doi: 10.1016/j.jtho.2022.06.012. - DOI - PubMed
1. Green M.R., Willey J., Buettner A., Lankford M., Neely D.B., Ramalingam S.S. Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists. J. Clin. Oncol. 2014;32:8097. doi: 10.1200/jco.2014.32.15_suppl.8097. - DOI